Tempus ECG-AF vs Eko Low Ejection Fraction Tool (ELEFT)
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary goal is to proactively identify older patients (65+) at elevated risk of developing new-onset atrial fibrillation within the next year, utilizing existing 12-lead ECG data. This tool is ideal for integrating into cardiology or geriatrics workflows to flag asymptomatic individuals for earlier follow-up and potential preventative strategies.
View Tempus ECG-AF →Choose Eko Low Ejection Fraction Tool (ELEFT) if…
Choose Eko Low Ejection Fraction Tool (ELEFT) if you need a rapid, non-invasive screening solution to aid in the early detection of low ejection fraction during routine physical examinations. This tool is best suited for general practitioners and cardiologists seeking to quickly assess heart failure risk at the point of care using a digital stethoscope.
View Eko Low Ejection Fraction Tool (ELEFT) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Unknown |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Eko Low Ejection Fraction Tool (ELEFT)Eko ELEFT integrates with digital stethoscopes for quick, point-of-care detection of low ejection fraction during routine physical exams, suggesting a highly streamlined and accessible workflow for a broad range of clinicians. Tempus ECG-AF, while integrated into existing systems, lacks a dedicated user interface and operates more in the background, potentially offering less direct user interaction.
Clinical Value
TieBoth tools offer significant clinical value by providing FDA-cleared AI algorithms for early detection of critical cardiac conditions. Tempus ECG-AF predicts future AF risk in a specific patient population, while Eko ELEFT aids in the early identification of low ejection fraction, a key indicator of heart failure. Both address crucial needs in proactive cardiac care.
Pricing & Value
Tempus ECG-AFTempus ECG-AF has a clear advantage with established CMS reimbursement available at a specific Medicare rate, providing a tangible financial benefit for healthcare providers. While Eko ELEFT has a Category III CPTu00ae Code, this supports data collection for efficacy and value but does not guarantee reimbursement.
Enterprise Readiness
TieBoth tools demonstrate strong enterprise readiness, being FDA-cleared, HIPAA compliant, and having BAAs. Tempus integrates into existing healthcare facility systems and EHRs, while Eko is a cloud-based enterprise solution that also supports telemedicine and virtual care, making both well-suited for large-scale deployment.
Innovation
Tempus ECG-AFTempus ECG-AF's innovation lies in its predictive capability, using AI to identify patients at increased risk of developing AF within the next 12 months from a standard 12-lead ECG, leveraging a massive dataset. Eko ELEFT is innovative in bringing AI-powered low EF detection to the point of care via digital stethoscopes, but Tempus's predictive nature offers a distinct advancement in clinical insight.
Support & Docs
Eko Low Ejection Fraction Tool (ELEFT)Eko Health provides a comprehensive Help Center with readily available user manuals, FAQs, and direct contact options for support via email and phone. While Tempus offers a resource center and general contact information, Eko's support structure appears more clearly defined and accessible for end-users.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Eko Low Ejection Fraction Tool (ELEFT) |
|---|---|---|
| Tool Name | Tempus ECG-AF | Eko Low Ejection Fraction Tool (ELEFT) |
| Primary Detection Goal | Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. | Aids clinicians in the early detection of low ejection fraction, a key indicator of heart failure. |
| Target Patient Population | Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified (Aids clinicians during routine physical exams, no specific age or exclusion criteria mentioned). |
| Input Data/Device | 12-lead ECG recordings (compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems). | ECG and heart sound recordings, integrates with Eko digital stethoscopes. |
| Core Technology | AI-based algorithm for 12-lead ECG analysis, trained on over 1.5 million ECGs from over 500,000 patients. | AI-powered low ejection fraction detection, analyzes ECG and heart sound recordings. |
| Result Speed | Not specified | Provides results in approximately 15 seconds. |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Eko Low Ejection Fraction Tool (ELEFT).
Frequently Asked Questions
More Comparisons
More matchups featuring Tempus ECG-AF or Eko Low Ejection Fraction Tool (ELEFT)
Backers
Who funded each tool's parent company.